A study investigating the safety, tolerability, absorption, excretion and effects of a new drug for the treatment of epilepsy.
Phase 1
- Conditions
- EpilepsyMedDRA version: 21.0Level: PTClassification code: 10015037Term: Epilepsy Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Registration Number
- CTIS2022-502638-17-00
- Lead Sponsor
- Trevena Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Male
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method